Selecting COVID-19 Patients for Treatment with Opaganib Based on a New Paradigm for Classification of Disease Severity

Time: 3:00 pm
day: Day One


  • Highlighting risk factors for treatment failure in SARS-CoV-2 ARDS pneumonia
  • Discussing clinical data about the efficacy of opaganib in a selected population of severe COVID-19 pneumonia
  • Identifying a new paradigm for disease severity in COVID-19 patients